Vaccines for immunotherapy of breast cancer and prostate cancer: New developments and comparative aspects

In Vivo

Volumn 16, Issue 6, 2002, Pages 405-415

  Minev, Boris R ^a   Guo, Fang ^a   Gueorguieva, Ivelina ^a   Kaiser, Hans E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Intl Soc Stud Compar Oncol   (United States)

Author keywords

Antigen presentation; Breast cancer; Cancer vaccines; Comparative oncology; Immunotherapy; Prostate cancer; Tumor associated antigens

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GAMMA INTERFERON; GANGLIOSIDE GM2 KEYHOLE LIMPET HEMOCYACIN CONJUGATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXASACCHARIDE GLOBO H KEYHOLE LIMPET HEMOCYANIN CONJUGATE; HLA A2 ANTIGEN; HORMONE; HYBRID PROTEIN; MELANOMA ANTIGEN; MUCIN 1; MUCIN 1 VACCINE; MUCIN ASSOCIATED GLYCAN EPITOPE STN KEYHOLE LIMPET HEMOCYANIN CONJUGATE; ONCOGENE NEU VACCINE; PROSTATE CARCINOMA TUMOR ANTIGEN 1; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTVAC; PROTEIN P53; PROVENGE; RECOMBINANT ACID PHOSPHATASE PROSTATE ISOENZYME; RECOMBINANT MOUSE ACID PHOSPHATASE PROSTATE ISOENZYME VACCINE; SRL 172; TELOMERASE; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA PROSTATE SPECIFIC ANTIGEN VACCINE; VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOTRANSPLANTATION; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG INFUSION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; GENETIC TRANSFECTION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; METASTASIS; NONHUMAN; ONCOGENE NEU; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; ACTIVE IMMUNIZATION; ANIMAL; BREAST TUMOR; FEMALE; IMMUNE SYSTEM; IMMUNOLOGY; MALE; PHYSIOLOGY; PROSTATE TUMOR; SPECIES DIFFERENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY, ACTIVE; MALE; PROSTATIC NEOPLASMS; SPECIES SPECIFICITY; VACCINES, SYNTHETIC;

EID: 0036862155     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Rammensee HG: Antigen presentation - Recent developments. Int, Arch Allergy Immunol 110: 299-307, 1996.
2. Yewdell JW and Bennink JR: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Advances in Immunology 52: 1-123, 1992.
3. Van Pel A, Van Der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van Den Eynde B, Uyttenhove C, Renauld JC and Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunological Reviews 145: 229-250, 1995.
4. De Plaen E, Lurquin C, Lethe B, Van Der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A and Boon T: Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12: 125-142, 1997.
5. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18: 175-182, 1997.
6. Wang RF: Human tumor antigens: Implications for cancer vaccine development. Journal of Molecular Medicine 77: 640-655, 1999.
7. Nestle FO, Alijagic S, Gilliet M, Sun M, Grabbe S, Durnmer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4: 328-332, 1998.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 4: 321-327, 1998.
9. Thumer B, Haendle I, Reoder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, Von Den Driesch P, Breocker EB, Steinman RM, Enk A, Keampgen E and Schuler G: Vaccination with mage-3A I peptide-pulsed mature, monocyt-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. Journal of Experimental Medicine 190: 1669-1678, 1999.
10. Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR and Rosenberg SA: T-cell recognition of human melanoma antigens. J Immunother 14: 88-93, 1993.
11. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P and Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. Journal of Experimental Medicine 178: 489-495, 1993.
12. Storkus WJ, Zeh HJD, Maeurer MJ, Salter RD and Lotze MT: Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 151: 3719-3727, 1993.
13. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF and Slingluff CLJ: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719, 1994.
14. Sahin U, Teureci O and Pfreundschuh M: Serologicla identification of human tumor antigens. Current Opinion in Immunology 9: 709-716, 1997.
15. Rammensee HG, Friede T and Stevanoviic S: MHC ligands and peptide motifs: First listing. Immunogenetics 41: 178-228, 1995.
16. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human [see comments]. Science 277: 955-959, 1997.
17. Parker KC, Bednarek MA and Coligan JE: Sheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. Journal of Immunology 152: 163-175, 1994.
18. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proceedings of the National Academy of Sciences of the United States of America 97: 4796-4801, 2000.
19. Mitchell MS, Kan-Mitchell J, Minev BR, Edman C and Deans RJ: A novel melanoma gene (MG50) encoding the interleukin I receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. Cancer Research 60: 6448-6456, 2000.
20. Hadden JW: The immunology and immunotherapy of breast cancer: An update. International Journal of Immunopharmacology 21: 79-101, 1999.
21. Knutson KL, Schiffnan K, Rinn K and Disis ML: Immunotherapeutic approaches for the treatment of breast cancer. Journal of Mammary Gland Biology and Neoplasia 4: 353-365, 1999.
22. Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH and Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Human Immunology 60: 1195-1206, 1999.
23. Nguyen T, Naziruddin B, Dintzis S, Doherty GM and Mohanakumar T: Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. International Journal of Cancer 81: 607-615, 1999.
24. Riethmuller G and Johnson JP: Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Current Opinion in Immunology 4: 647-655, 1992.
25. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G and Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status [letter; comment]. Journal of the National Cancer Institute 90: 1099-1101, 1998.
26. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR and Riethmuller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. Journal of the National Cancer Institute 85: 1419-1424, 1993.
27. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. Journal of the National Cancer Institute 87: 1588-1592, 1995.
28. Braun S, Hepp F, Sommer HL and Pantel K: Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. International Journal of Cancer 84; 1-5, 1999.
29. Minev BR, Chavez FL and Mitchell MS: Cancer vaccines: Novel approaches and new promises. Pharmacology and Therapeutics 81: 121-139, 1999.
30. Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D and Hamilton JM: Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res Treat 38: 27-39, 1996.
31. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG and Bordignon C: Expression of the MAGE gene family in primary and metastatic human breast cancer: Implications for tumor antigen-specific immunotherapy. International Journal of Cancer 64: 216-221, 1995.
32. Barratt-Boyes SM: Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol. Immunother 43: 142-151, 1996.
33. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M and Kayibanda M: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25: 1765-1769, 1995.
34. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E and Livingston RB: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20, 1994.
35. Mokbel K: The role of telomerase in breast cancer. European Journal of Surgical Oncology 26: 509-514, 2000.
36. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA and Shay JW: Telomerase activity in human breast tumors. Journal of the National Cancer Institute 88: 116-122, 1996.
37. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J and Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985.
38. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME and King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8: 103-112, 1990.
39. Toikkanne S, Helin H, Isolal J and Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 10: 1044-1048, 1992.
40. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
41. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER2-neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997.
42. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Loannides CG and Murray JL: Proliferative and cytokine responsers to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 4: 2015-2024, 1998.
43. Peoples GE, Goedegebuure PS Smith R, Linehann DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neui-derived peptide. Proc Natl Acad Sci U.S.A. 92: 432-436, 1995.
44. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
45. Disis ML, Smith JW, Murphy AE, Chen W and Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54: 1071-1076, 1994.
46. Minev BR: e.a. Unpublished observations.
47. Disis ML and Cheever MA: HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 343-371, 1997.
48. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA and Sherman LA: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum Immunol 52: 109-118, 1997.
49. Disis ML, Grabstein KH, Sleath PR and Cheever MA: Generation of immunity to the HER2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clinical Cancer Research 5: 1289-1297, 1999.
50. Zaks TZ and Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58: 4902-4908, 1998.
51. Knutson KL, Schiffman K and Disis ML: Immunization with a HEER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001.
52. Disis ML and Schiffinan K: Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28: 12-20, 2001.
53. Brossart P, Wirth S, Stuhler G, Reichardt VL, Kanz L and Brugger W; Induction of cytotoxic T lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
54. Apostolopoulos V and McKenzie IF: Cellular mucins: Targets for immunotherapy. Crit Rev Immunol 14: 293-309, 1994.
55. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J and Barratt-Boyes SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61-89, 1995.
56. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
57. Hilkens J, Vos HL, Wesseling J, Boer M, Storm J, Van Der Valk S, Calafat J and Patricia C: Is episialin/MUC1 involved in breast cancer progression? Cancer Lett 90: 27-33, 1995.
58. MacLean GD. Reddish MA and Longenecker BM: Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adeno-carcinoma patients. J Immunother 20: 70-78, 1997.
59. Fung PY. and Longenecker BM: Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Research 51: 1170-1176, 1991.
60. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW and Nadler LM: Breast cancer- associated antigen, DF3/MUC 1, induces apoptosis of activated human T cells. Nature Medicine 2: 1367-1370, 1996.
61. Agrawal B, Krantz MJ, Reddish MA and Longenecker BM: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4: 43-49, 1998.
62. Bamd DL, Lan MS, Metzgar RS and Finn OJ: Specific, major histocompatibility complex unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America 86: 7159-7163, 1989.
63. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K and Yachi A: Expression of MUC1 on myeloma cells and induction and HLA- unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153: 2102-2109, 1994.
64. Domenech N, Henderson RA and Finn OJ: Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155; 4766-4774, 1995.
65. Agrawal B, Reddish MA and Longenecker BM: In vitro induction of MUC-1 peptide- specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157: 2089-2095 1996.
66. Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS and Longenecker BM: Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. International Journal of Cancer 76: 817-823, 1998.
67. Apostolopoulos V, Haurum JS and McKenzie IF: MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 27: 2579-2587, 1997.
68. Apoptolopoulos V, Karanikas V, Haurum JS and McKenzie IF: Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159: 5211-5218, 1997.
69. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L and Brugger W: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317, 1999.
70. Longenecker BM, Reddish M, Koganty R and MacLean GD: Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann N Y Acad Sci 690: 276-291, 1993.
71. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD and Longenecker BM: Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. Journal of Immunotherapy 22: 54-66, 1999.
72. Reddish MA, MacLean GD, Poppema S, Berg A and Longenecker BM: Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 42: 303-309, 1996.
73. MacLean GD, Miles DW, Rubens RD, Reddish MA and Longenecker BM: Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low- dose intravenous cyclophoshamide. J Immunother Emphasis Tumor Immunol 19: 303-316, 1996.
74. Holmberg LA, Oparin DV, Gooley T, Lilleby K, Bensinger W, Reddish MA, MacLean GD, Longenecker BM and Sandmaier BM: Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE-STn-KLH cancer vaccine. Bone Marrow Transplant 25: 1233-1241, 2000.
75. Holmberg LA and Sandmaier BM; Theratope((R)) vaccine (STn-KILH). Expert Opin Biol Ther 1: 881-891, 2001.
76. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L and Livingstone PO: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6: 1693-1701, 2000.
77. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
78. Small EJ and Srinivas S: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76: 1428-1434, 1995.
79. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM et al. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer [see comments]. Journal of Clinical Oncology 10: 881-889, 1992.
80. Cher ML, Shinohara K, Breslin S, Vapnek J and Carroll PR: High failure rate associated with long-term follow-up neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. British Journal of Urology 75: 771-777, 1995.
81. Afrin LB and Stuart RK: Medical therapy of prostate cancer. Journal South Carolina Medical Association 90: 231-236, 1994.
82. Diamandis EP: Prostate-specific antigen: A cancer fighter and a valuable messenger? Clinical Chemistry 46: 896-900, 2000.
83. Horoszewicz JS, Kawinski E and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Research 7: 927-935, 1987.
84. Murphy G, Tjoa B, Ragde H, Kenny G and Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostaste 29: 371-380, 1996.
85. Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI and Fisher PB: Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proceedings of the National Academy of Sciences of the United States of America 93: 7252-7257, 1996.
86. Fong L, Ruegg CL, Brockstedt D, Engleman ED and Laus R: Induction of tissue-specific autoimmune prostatis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. Journal of Immunology 159: 3113-3117, 1997.
87. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC; KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p 11.2 [see comments]. Science 268: 884-886, 1995.
88. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M and Witte ON: Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 95: 1735-1740, 1998.
89. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova Gs, Shay JW and Coffey DS: Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Research 56: 218-222, 1996.
90. Eaton JD, Perry MJ, Nicholson S, Guckian M, Rusell N, Whelan M and Kirby RS: Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89: 19-26, 2002.
91. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF and Nelson WG: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor using ex vivo gene transfer. Cancer Research 59: 5160-5168, 1999.
92. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K., Lloyd KO, Livingston PO, Danishefsky SJ and Scher HI: Carbhydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of Sciences of the United States of America 96: 5710-5715, 1999.
93. Slovin SF, Ragupathi G and Israel R: Ganglioside vaccines in relapsed prostate cancer (PC): Experience with GM2-KLH conjugate plus the immunologic adjuvant, QS2 1 -A trial comparing QS21 doses [abstr 1214]. In Proc Am Soc Clin Oncol pp. 316Aa.
94. Slovin SF, Livingston P, Keeperman K, Mhatre S, Danishefsky S, Glazewski J, Adluri S, Zhang S, Gordils J and Scher HI: Targeted therapy in prostate cancer: Vaccination with a glycoprotein, MUC-1-KLH-QS21 peptide conjugate. Journal of Urology 157: 160, 1997.
95. Slovin SF, Kelly WK and Scher HI: Immunological approaches for the treatment of prostate cancer. Seminars in Urologic Oncology 16: 53-59, 1998.
96. Meidenbauer N, Harris DT, Spitler LE and Whiteside TL: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43: 88-100, 2000.
97. Sandra MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D and Monite JE: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53: 260-266, 1999.
98. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, and Kufe DW: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6: 1632-1638, 2000.
99. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
100. Sallusto F, Cella M, Danieli C and Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products [see comments]. J Exp Med 182: 389-400, 1995.
101. Kiertscher SM and Roth MD: Human CD 14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol 59; 208-218; 1996.
102. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I- restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995.
103. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA and Hwu P: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186: 1213-1221, 1997.
104. Mehta-Damani A, Markowicz S and Engleman EG: Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 153: 996-1003; 1994.
105. Valone F, Small E, Peshwa MV, Strang G, Laus R, Ruegg C and Van Schooten W: Phase I trial of dendritic cell-based immunotherapy with APC8015 for hormone-refractory prostate cancer (HRPC). Proceedings of the American Association for Cancer Research Annual Meeting 39: 173, 1998.
106. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL and Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272-278, 1997.
107. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL and Murphy GP: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 3944, 1998.
108. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL and Murphy GP: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39: 291-297, 1999.
109. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL and Murphy GP: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125-129, 1999.
110. Lodge PA, Jones LA, Bader RA, Murphy GP and Salgaller ML: Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Research 60: 829-833, 2000.
111. Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM and Jarisch J: Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 43: 59-62, 2000.
112. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL and Engleman EG: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167: 7150-7156, 2001.
113. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV and Valone FH: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903, 2000.
114. Heiser A, Dahm PR: Yancey D, Maurice MA, Boczkowski D, Nair SK, Gilboa E and Vieweg J: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. Journal of Immunology 164: 5508-5514, 2000.
115. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedwiecki D, Gilboa E and Vieweg J: Autologous dendritic cells transfected with prostatespecific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417, 2002.
116. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Atlankova I, Georgiev G, Petrov S and Meryman HT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 38: 208-217, 2000.
117. Mincheff M, Atlankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva E, Kurteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, Lissitchkov T, Chernozemski I and Meryman HT: In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 39: 125-132, 2001.
118. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM and Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57: 5534-5541, 1997.
119. Fong L, Brockstedt D, Benike C, Wu L and Engleman EG: Dendritici cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259, 2001.
120. Nowak RM: Walker's Mammals of the World., Vol. 2, p. 1629. Baltimore: Johns Hopkins University Press, 1991.
121. Dellmann H: Textbook of Veterinary Histology, p. 380. Baltimore: Williams & Wilkins, 1998.
122. Bunton TE: Use of non-mammalian species in bioassays for carcinogenicity. IARC Sci Publ 151-184, 1999.
123. Kaiser HE: Species-Specific Potential of Invertebrates for Toxicological Research., p. 224. Baltimore: University Park Press, 1980.
124. Kaiser HE: Comparative importance of the lymphatic system during neoplastic progression: Lymphohematogenous spreading. In: H. E. Kaiser (ed.), Fundamental Aspects of Cancer, Vol. 1, pp. 98-134. Dordrecht-London: Kluwer Academic Publishers, 1989
125. Griesemer RA and Eustis SL: Gender differences in animal bioassays for carcinogenicity. J Occup Med 36: 855-859, 1994.
126. Cardiff RD and Wellings SR: The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 4: 105-122, 1999.
127. Hildemann WH, Johnson IS and Jokiel PL: Immunocompetence in the lowest metazoan phylum: Transplantation immunity in sponges. Science 204: 420-422, 1979.
128. Hultmark D: Immune reactions in Drosophila and other insects: A model for innate immunity. Trends Genet 9: 178-183, 1993.
129. Meister M, Hetru C and Hoffmann JA: The antimicrobial host defense of Drosophila. Curr Top Microbiol Immunol 248: 17-36, 2000.
130. Burnet FM: A modification of Jenne's theory of antibody production using the concept of clonal selection. CA Cancer J Clin 26: 119-121, 1976.
131. Tonegawa S: Somatic generation of antibody diversity. Nature 302: 575-581, 1983.
132. Litman GW, Berger L, Murphy K, Litman R, Hinds K and Erickson BW: Immunoglobulin VH gene structure and diversity in Heterodontus, a phylogenetically primitive shark. Proc Natl Acad Sci USA 82: 2082-2086, 1985.
133. Bartl S and Weissman IL: Isolation and characterization of major histocompatibility complex class IIB genes from the nurse shark. Proc Natl Acad Sci USA 91: 262-266, 1994.
134. Toes RE, Offringa R, Blom RJ, Melief CJ and Kast WM: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93: 7855-7860, 1996.
135. Webb S, Morris C and Sprent J: Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity. Cell 63: 1249-1256, 1990.
136. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A and Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11: 729-766, 1993.
137. Hoon DS, Yuzuki D, Hayashida M and Mortony DL: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen J Immunol 154: 730-737, 1995.